Sign inJoin free

Home › Experts

Experts

Every analyst, fund manager and economist who has been on ausbiz. Open an expert to see all of their videos, or follow them to get new ones in My ausbiz.

On ausbiz today

Full schedule →
Expertise

10 experts in Biotech

Stuart RobertsCo-FounderStocks Down Under

By background I am an investment professional who did Australian equity research from the late 1990s until early 2015 and again from mid-2016. For a lot of the time I have worked as an analyst I focused on healthcare and biotechnology, and the Life Sciences has become a passion of mine. My forte is making complex, technology-based investment ideas easy to understand. In January 2015 I joined my first biotechnology company, a cancer immunotherapy play called Prima Biomed (Nasdaq: PBMD) and had a great time with them until November 2015. From January until May 2016 I took care of investor relations for another cancer immunotherapy company, Imugene (ASX: IMU). In June 2016 I returned to the equities analyst game with the founding of NDF Research. Two years later in June 2018 I teamed up with Marc Kennis to found Pitt Street Research with the aim of providing issuer-sponsored equity research to the entire spectrum of ASX-listed companies. Please note that any advice given by NDF Research or Pitt Street Research is GENERAL advice.

105 videos · last on 6 Nov

See videos
Jason SegalFounderThe Arm Chair Analyst

Jason Segal is the Founder and Analyst at The Armchair Analyst, an investment newsletter focused on making small-cap biotech investing more accessible to everyday investors. Previously, he spent six years at Next Investors, where he covered emerging ASX companies across the resources and biotech sectors.

2 videos · last on 30 Oct

See videos
Matthew LeonardManaging DirectorOcean Sciences

Accomplished and internationally proven business development professional offering an outstanding record of achievement over 12 years in demanding, complex and highly competitive markets requiring sophisticated relationship development skills and a commercially astute approach to identifying and materialising profitable revenue opportunities. Expertise has been established across the advertising, marketing and media event management sector, with recent focus on linking opportunities with high net worth individuals throughout Asia. Effective collaboration and a relentless passion to drive positive business outcomes have been integral to delivering in excess of USD10M of revenue and over $50M in potential opportunity.

1 video · last on 21 Oct

See videos
Michael FrazisPortfolio ManagerFrazis Capital Partners

Michael is the founder and CEO of Frazis Capital Partners. Prior to founding the firm, Michael spent five years in private equity in London, after completing internships in Goldman Sachs Special Situations Group and the Boston Consulting Group. Michael read Chemistry at Oxford University, and has a Masters of Finance from the London School of Economics.

23 videos · last on 9 Oct

See videos
Sarah ThomCFOCochlear

Sarah Thom is the CFO of Cochlear and is passionate about work that helps make people’s lives better. She serves on the Board of Children’s Medical Research Foundation and is a member of Chief Executive Women. She has deep experience defining and delivering large-scale change and innovation across complex organisations and ecosystems, with recognised expertise in strategy development and delivery, major investment evaluation and whole-of-business transformation.

1 video · last on 18 Aug

See videos
James GrahamCEO & MDRecce Pharmaceuticals

Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals. He brings extensive experience in marketing, business development, and the commercialisation of early-stage technologies with global potential. With a proven track record of growing globally focused companies, Mr Graham has applied his expertise to Recce, including serving on its Board of Directors. He has participated in nearly every capital raise to date, demonstrating a strong commitment to expanding Recce’s commercial opportunities and clinical programs.

1 video · last on 14 July

See videos
Paul GavinCEOAvecho Biotechnology

Paul Gavin is the Chief Executive Officer at Avecho Biotechnology, bringing expertise backed by a Doctor of Philosophy. Their background reflects a strong focus on biotechnology and pharmaceutical innovation. Paul's leadership steers Avecho's strategic direction within the pharmaceutical sector. Drawing on a background in scientific research, they previously served as Chief Scientific Officer at Avecho Biotechnology. In this role, Paul provided scientific oversight and managed research initiatives. Prior to this, activities involved serving as Vice President, Research & Development, contributing to product development and innovation strategy. Paul's academic foundation includes a Doctor of Philosophy and a Bachelor of Science from Monash University

1 video · last on 14 July

See videos
Jason CarrollCEO & Executive DirectorEntropy Neurodynamics

With 34 years of experience in the healthcare industry, Jason is a professional, experienced and highly successful leader who has delivered superior performance and high-functioning teams across four different countries and multiple healthcare categories. He is currently the CEO & Managing Director of Tryp Therapeutics, based in Sydney, Australia. In his previous role, as Managing Director of iNova Pharmaceuticals Philippines, iNova was the fastest growing multinational pharmaceutical company in the Country over a 5 year period, tripling sales and quadrupling profit and, was awarded by Nicholas Hall for the Best Digital Marketing Launch Globally for DIFFLAM FORTE Throat Spray in 2019. Jason's core competencies include Strategic Market insight, Licensing & Acquisition, Program Development & Execution, Customer Relationship Development for the long term, Sales, Marketing, Product Development, Pharmaceutical Manufacturing as well as a unique skillset in identifying and promoting Talent Development. Jason utilises his skills (testing higher than 99.9% vs global population) in Abstract Reasoning and Numerical Analysis in order to build unique and lateral insight, response and superior r

1 video · last on 7 July

See videos
Jon PilcherCEO and MDNeuren Pharma

Jon joined Neuren in August 2013 as CFO and was appointed CEO in May 2020. He has played a central role in all aspects of Neuren's R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux (ASX: ACR) throughout a period that included Acrux's IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of senior financial positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK.

1 video · last on 2 July

See videos
Yujing LimCEOOsteopore

I conduct research on biomaterials for tissue engineering and regenerative medicine, and prior to joining Osteopore I published 14 articles in internationally peer-reviewed journals. Since joining Osteopore in November 2014, I have been significantly involved in the company’s many regulatory and quality milestones, as well as leading the expansion of the product and therapy portfolio. I am committed to developing new ways to improve the lives of people across the globe.

1 video · last on 10 Mar

See videos

Experts’ views are their own and general in nature. They are not recommendations by ausbiz or ausbiz Invest, and experts may hold the investments they discuss. Consider your own circumstances and get professional advice.

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy